Pay in 4 interest-free payments of $7.21 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Once again, GHK-Cu appeared to mediate its effects through decreased TNF-alpha and IL-6 expression [11]
The compound has progressed through Phase I and Phase II trials with promising results, demonstrating both efficacy and safety in multiple patient populations
What the dose-response data shows, how it differs from titration, and the cost and safety risks.
3 weeks and Im down 7 lbs
BPC-157 came off the FDA Category 2 list effective April 23, 2026, and is one of the seven peptides under PCAC review for 503A compounding eligibility in July 2026
It supports angiogenesis (blood vessel formation), encourages fibroblast migration (essential for rebuilding damaged tissue), and helps regulate nitric oxide a molecule that influences blood flow, inflammation, and cellular repair
US$ 24.87
US$ 21.08
US$ 20.88
